论文部分内容阅读
肝细胞癌合并胆管癌栓是肝癌的一种特殊类型，发生率为0.5%~2.5%，疾病进展快、预后差，目前国内外尚无相关的诊断与治疗共识，造成该疾病的治疗极不规范。中国医师协会肝癌专业委员会基于国内外本领域研究获得的循证医学证据，并结合我国临床实践，制订《肝细胞癌合并胆管癌栓多学科诊治中国专家共识（2020版）》。该共识针对肝细胞癌合并胆管癌栓的临床表现、诊断及分型、外科治疗、辅助治疗以及其他局部、区域性和系统性治疗进行系统阐述，旨在规范、普及和提高对肝细胞癌合并胆管癌栓的诊断和多学科治疗水平，改善该疾病总体预后。“,”Bile duct tumor thrombus(BDTT) is a special type of hepatocellular carcinoma(HCC). The incidence of BDTT is 0.5%-2.5% of all HCC patients. BDTT progresses rapidly and has a very poor prognosis. Now there is no consensus of diagnosis and treatment of BDTT, resulting in the nonstandard treatment of BDTT. Based on the evidence-based medical evidence obtained from the international studies on BDTT in recent years, as well as the clinical practice in our country, the Chinese Association of Liver Cancer of Chinese Medical Doctor Association formulates the “Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with bile duct tumor thrombus (2020)”, which has systematically addressed the clinical manifestations, diagnostic methods, staging, surgical and adjuvant treatment, and other local, regional and systemic treatments of HCC with BDTT. This consensus is designed to standardize and popularize the diagnosis and multidisciplinary treatment of BDTT to improve overall prognosis of the disease.